Cargando…

Functionalized MoS(2) Nanosheets as Multi-Gene Delivery Vehicles for In Vivo Pancreatic Cancer Therapy

Transition metal dichalcogenides (TMDCs) are categorized as novel two-dimensional (2D) nanomaterials with unique physical and chemical properties, bearing varied applications in medical and materials sciences. However, only a few works report the application of TMDCs for gene therapy in cancer treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Feng, Anderson, Tommy, Panwar, Nishtha, Zhang, Kang, Tjin, Swee Chuan, Ng, Beng Koon, Yoon, Ho Sup, Qu, Junle, Yong, Ken-Tye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6170332/
https://www.ncbi.nlm.nih.gov/pubmed/30324083
http://dx.doi.org/10.7150/ntno.27308
_version_ 1783360629521776640
author Yin, Feng
Anderson, Tommy
Panwar, Nishtha
Zhang, Kang
Tjin, Swee Chuan
Ng, Beng Koon
Yoon, Ho Sup
Qu, Junle
Yong, Ken-Tye
author_facet Yin, Feng
Anderson, Tommy
Panwar, Nishtha
Zhang, Kang
Tjin, Swee Chuan
Ng, Beng Koon
Yoon, Ho Sup
Qu, Junle
Yong, Ken-Tye
author_sort Yin, Feng
collection PubMed
description Transition metal dichalcogenides (TMDCs) are categorized as novel two-dimensional (2D) nanomaterials with unique physical and chemical properties, bearing varied applications in medical and materials sciences. However, only a few works report the application of TMDCs for gene therapy in cancer treatment. Here, we engineer a multi-gene delivery system based on functionalized monolayer MoS(2), which can co-deliver HDAC1 and KRAS small interfering RNAs (siRNAs) to Panc-1 cancer cells for combinational cancer therapy. The synergistic effect of gene silencing therapy and NIR phototherapy is demonstrated by inhibition of both genes, in vitro cell growth rate, and in vivo tumor volume growth rate, exemplifying pre-eminent anticancer efficacy. This anti-tumor effect is a result of the photothermal effect of MoS(2) induced by NIR excitation and inactivation of HDAC1 and KRAS genes, which consequently bring about apoptosis, inhibit migration, and induce cell cycle arrest in the treated Panc-1 cells. Moreover, good biocompatibility and reduced cytotoxicity of MoS(2)-based nanocarriers enable their metabolism within in vitro and in vivo mouse models over a prolonged duration without any evident ill-effects. In summary, we demonstrate the promising potential of low-toxicity, functionalized MoS(2) nanocarriers as a biocompatible gene delivery system for in vivo pancreatic adenocarcinoma therapy.
format Online
Article
Text
id pubmed-6170332
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-61703322018-10-15 Functionalized MoS(2) Nanosheets as Multi-Gene Delivery Vehicles for In Vivo Pancreatic Cancer Therapy Yin, Feng Anderson, Tommy Panwar, Nishtha Zhang, Kang Tjin, Swee Chuan Ng, Beng Koon Yoon, Ho Sup Qu, Junle Yong, Ken-Tye Nanotheranostics Research Paper Transition metal dichalcogenides (TMDCs) are categorized as novel two-dimensional (2D) nanomaterials with unique physical and chemical properties, bearing varied applications in medical and materials sciences. However, only a few works report the application of TMDCs for gene therapy in cancer treatment. Here, we engineer a multi-gene delivery system based on functionalized monolayer MoS(2), which can co-deliver HDAC1 and KRAS small interfering RNAs (siRNAs) to Panc-1 cancer cells for combinational cancer therapy. The synergistic effect of gene silencing therapy and NIR phototherapy is demonstrated by inhibition of both genes, in vitro cell growth rate, and in vivo tumor volume growth rate, exemplifying pre-eminent anticancer efficacy. This anti-tumor effect is a result of the photothermal effect of MoS(2) induced by NIR excitation and inactivation of HDAC1 and KRAS genes, which consequently bring about apoptosis, inhibit migration, and induce cell cycle arrest in the treated Panc-1 cells. Moreover, good biocompatibility and reduced cytotoxicity of MoS(2)-based nanocarriers enable their metabolism within in vitro and in vivo mouse models over a prolonged duration without any evident ill-effects. In summary, we demonstrate the promising potential of low-toxicity, functionalized MoS(2) nanocarriers as a biocompatible gene delivery system for in vivo pancreatic adenocarcinoma therapy. Ivyspring International Publisher 2018-08-25 /pmc/articles/PMC6170332/ /pubmed/30324083 http://dx.doi.org/10.7150/ntno.27308 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Yin, Feng
Anderson, Tommy
Panwar, Nishtha
Zhang, Kang
Tjin, Swee Chuan
Ng, Beng Koon
Yoon, Ho Sup
Qu, Junle
Yong, Ken-Tye
Functionalized MoS(2) Nanosheets as Multi-Gene Delivery Vehicles for In Vivo Pancreatic Cancer Therapy
title Functionalized MoS(2) Nanosheets as Multi-Gene Delivery Vehicles for In Vivo Pancreatic Cancer Therapy
title_full Functionalized MoS(2) Nanosheets as Multi-Gene Delivery Vehicles for In Vivo Pancreatic Cancer Therapy
title_fullStr Functionalized MoS(2) Nanosheets as Multi-Gene Delivery Vehicles for In Vivo Pancreatic Cancer Therapy
title_full_unstemmed Functionalized MoS(2) Nanosheets as Multi-Gene Delivery Vehicles for In Vivo Pancreatic Cancer Therapy
title_short Functionalized MoS(2) Nanosheets as Multi-Gene Delivery Vehicles for In Vivo Pancreatic Cancer Therapy
title_sort functionalized mos(2) nanosheets as multi-gene delivery vehicles for in vivo pancreatic cancer therapy
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6170332/
https://www.ncbi.nlm.nih.gov/pubmed/30324083
http://dx.doi.org/10.7150/ntno.27308
work_keys_str_mv AT yinfeng functionalizedmos2nanosheetsasmultigenedeliveryvehiclesforinvivopancreaticcancertherapy
AT andersontommy functionalizedmos2nanosheetsasmultigenedeliveryvehiclesforinvivopancreaticcancertherapy
AT panwarnishtha functionalizedmos2nanosheetsasmultigenedeliveryvehiclesforinvivopancreaticcancertherapy
AT zhangkang functionalizedmos2nanosheetsasmultigenedeliveryvehiclesforinvivopancreaticcancertherapy
AT tjinsweechuan functionalizedmos2nanosheetsasmultigenedeliveryvehiclesforinvivopancreaticcancertherapy
AT ngbengkoon functionalizedmos2nanosheetsasmultigenedeliveryvehiclesforinvivopancreaticcancertherapy
AT yoonhosup functionalizedmos2nanosheetsasmultigenedeliveryvehiclesforinvivopancreaticcancertherapy
AT qujunle functionalizedmos2nanosheetsasmultigenedeliveryvehiclesforinvivopancreaticcancertherapy
AT yongkentye functionalizedmos2nanosheetsasmultigenedeliveryvehiclesforinvivopancreaticcancertherapy